The diagnostic performance of a new enzyme linked immunosorbent assay for the cardiac structural protein troponin T in the differential diagnosis of ischaemic cardiac damage was assessed. A well documented set of patients admitted to the coronary care unit of a district general hospital were studied. At a cutoff value of O' 2 j.tg/L, troponin T measurements 12-24 h after admission or 12-16 to 24-48 h from onset of chest pain showed an overall efficiency of 97·60/0 for diagnosis of proven myocardial infarction. Troponin T was not detectable in patients when ischaemic heart disease could be excluded but was present in four patients with angina. Detectable troponin T in these angina patients was associated with subsequent cardiac events.
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An assay for the cardiac structural protein troponin T has been developed 1 and is now commercially available. It has been suggested that measurement of troponin T is an alternative and superior technique to measurement of the MB isoenzyme of creatine kinase (CK-MB)for the diagnosis of myocardial infarction.P" We have studied the diagnostic performance of troponin T for differential diagnosis of suspected myocardial infarction and examined the possible confounding effect of sample timing and thrombolytic therapy on diagnostic accuracy. We compared the diagnostic performance of troponin T determinations with that of an accurately timed CK-MB concentration measurement.
METHODS
Consecutivepatients admitted to the coronary care unit (CCU) with cardiac symptoms were studied. All were assessed by clinical examination, serial electrocardiography,and measurement of aspartate transaminase (AST) and hydroxy butyrate dehydrogenase (HBD) activity for three consecutive Correspondence: Dr P 0 Collinson, Department of Chemical Pathology, Mayday University Hospital, Thornton Heath, Surrey CR7 7YE, UK. days after admission. The time from onset of symptoms to collection of the first sample was recorded in all cases. Full clinical details were obtained on all patients including follow up data and clinical outcome.
On patients in whom myocardial infarction had been excluded further investigation was carried out by stress electrocardiography or radionuclide (dipyridamole enhanced thallium) scintigraphy. Coronary angiography was performed on patients with positive stress electrocardiograms or radionuclidescans, or when equivocalinvestigationswere accompanied by a strong clinical suspicion of ischaemic heart disease. When ischaemic heart disease was excluded an alternative diagnosis was sought.
Infarction was judged to have occurred in patients with a history of chest pain accompanied by the development of Q waves, or ischaemic ECG changes and sudden death within 72 h of admission. S-T and T wave changes were taken to indicate infarction when serial AST and HBD values exceeded the upper reference limit or there was evidence from cardiac imaging in patients without previous myocardial infarction (occluded vessels on subsequent angiography, an akinetic or hypo kinetic segment on echocardiography or angiography or a persistent filling defect on radionuclide scintigraphy) .
A diagnosis of angina was made in patients with clinical features suggestive of ischaemic heart disease prior to admission, no further symptoms following admission and no change in serial AST and HBD values and either transient S-T changes or a positive stress ECG.
Unstable angina was diagnosed in patients with chest pain lasting for 30 or more minutes when one (or more) of the following occurred after admission: I Persistent S-T segment shift or T wave changes without changes in serial AST or HBD values. 2 Further cardiac symptoms (chest pain, chest discomfort or dyspnoea) with development of S-T segment shift or T wave changes. 3 An initially normal ECG with serial AST and HBD values below the upper reference limit during the first 48 h following admission but persistent chest pain and development of either ECG changes typical or myocardial infarction or serial AST and HBD values exceeding the upper reference limit or both 48 h after admission. Non-ischaemic chest pain (NICP) was diagnosed when angina could be excluded by a definite alternative source of the chest pain or an atypical history with a negative stress ECG.
Ninety-three patients were studied, 66 men and 27 women, age range 36 to 82 years, median 62 years. Using the criteria defined above, 53 patients were classified as having sustained acute myocardial infarction, 4 as unstable angina, 23 as ischaemic heart disease without acute infarction and 13 as non-ischaemic chest pain. In the acute myocardial infarction group, 22 received thrombolytic therapy with acyl plasminogen streptokinase activated complex (APSAC, Eminase; Beecham Research Laboratories, Welwyn Garden City, UK), and eight with streptokinase.
Blood samples were obtained from patients on admission and 2, 4, 8, 12, 24 and 48 h from admission. Sera were separated on the CCU, stored at 4°C and analysed for creatine kinase (CK) within 24 h, stored frozen at -20°C until analysed for CK-MB concentration or stored frozen at -70°C until analysed for troponin T concentration. CK-MB determinations were performed only on the 0-8 h samples, since previous studies had shown maximal diagnostic accuracy 8 h from admission." CK and troponin T were determined on all samples.
AST and HBD were measured at 37°C by optimized methods on a Perspective analyser (American Ann Clin Biochem 1993; 30 Monitor, Burgess Hill, UK) by the manufacturer's recommended methods. The manufacturer's reagents were used for A5T and commercially supplied reagents used for HBD (Merckotest HBDH, BDH Diagnostics, Poole, UK).
Total CK was measured at 30°C by optimized methods, using commercially supplied reagents (CK NAC opt., Boehringer Mannheim (UK) Ltd, Lewes, UK). All determinations were made using a centrifugal analyser (Encore, Baker Instruments, Windsor, UK).
CK-MB concentration was determined using the Hybritech Tandem-E CKMB assay system (Hybritech, Nottingham, UK) as recommended by the manufacturer. This technique uses monoclonal antibodies to the Band M subunits in a two-site sandwich assay specific for CK-MB protein.
Troponin-T was determined by an enzyme linked immunosorbent assay (ELISA) using the E5-300 Immunoassay analyser (Boehringer Mannheim UK Ltd, Lewes, UK). Two hundred microlitres of serum sample is pipetted into streptavidin coated tubes and incubated at 37°C for 60 min with antibody reagent. Troponin-Tin the sample binds to two antibodies, one labelled with biotin the other with horse-radish peroxidase. The streptavidin-biotin link binds the complex to the wall of the assay tube. Washing of the coated tube removes unbound enzyme conjugate. Quantitation is achieved by the addition of a sodium perborate substrate and monitoring the increase in absorbance of a di-ammonium 2,2 azino-bis(3-ethylbenzothiazoline-6-sulphate) chromogen at 422 nm after 25 min at 37°C. With an initial incubation of 60 min to allow antibodyI antigen complex formation, the total assay time is 2 h including sample handling. Inter-assay imprecision (coefficient of variation) was 12' 31170 , 7' 71170 and 4· 21170 at mean troponin T levels of 0'13 ",giL, 1·6 ",giL and 7·1 ",giL, respectively. Intra-assay imprecision was 2· 01170 and 1· 91170 at mean troponin T values of 1·7 I48/L and 7· 0 ",giL, respectively.
Receiver operator characteristic (ROC) curves were generated from all the troponin T data using sample time from admission and sample time Sensitivity 100 analysis using the selected cut-off for troponin T. Optimized cutoffs for CK and CK-MB concentration, taken from previous studies,6-8 were 120U/L for CK and 10 /Lg/L for CK-MB. Sensitivity and (100-specificity) was plotted against time from admission for all troponin T data without correction for time of onset of chest pain, including patients with symptoms of more than 12 h duration on admission, to determine the importance of the time of measurement.
Direct comparison with an optimized diagnostic strategy was then performed by exclusion of patients with symptoms of more than 12 h duration on admission. Sensitivity and (100 -specificity) plots were generated for troponin T, CK and CK-MB using time from admission and time from onset of chest pain. All plots were constructed including and excluding patients receiving thrombolytic therapy.
RESULTS
The optimized diagnostic cutoff for troponin was O' 2 /Lg/L for all the sample times studied. The effect of altering the diagnostic cut-off on sensitivity, specificity and efficiency at 12 h is summarized in Table 1 . Efficiency is maximal at 96·92070 for values between O' 2 to O· 3 /Lg/L but sensitivity falls with a value above O' 2 /Lg/L. Sensitivityand (100 -specificity) curves following admission for all patients, including those with symptoms of more than 12 h duration on admission are shown in Fig. 1 . Troponin T reaches optimum diagnostic performance 12 h from admission and remains 100% sensitive up to 24 h. Comparison of the curves shows that exclusion of patients receiving thrombolytic therapy has no effect on the diagnostic Time from admission (h) Correcting for time from onset of chest pain and excluding those with symptoms of more than 12 h duration on admission improves the diagnostic performance (Fig. 2) . Sensitivity for troponin T increases to 1001170 at 48 h from admission or onset of symptoms hence the diagnostic window for troponin T is increased to 48 h from admission or onset of symptoms.
Two patients classified as non-infarct showed troponin values exceeding O·2 /Lg/L. One had sustained a myocardial infarction 10 days previously. The second had unstable angina with elevation of CK-MB concentrations which just failed to exceed the diagnostic cut-off. It is likely that this patient had a non Q wave infarction. Data for both of these patients are presented in Table 2 . Exclusion of both these cases increases the specificity of troponin T to 1001170.
Four patients with a final diagnosis of angina had detectable (> O·1 /Lg/L) troponin values. All four had cardiac events during the subsequent 6 months. This did not occur in the remaining angina patients. No patients where ischaemic heart disease was excluded had detectable troponin T.
DISCUSSION
The cutoff of O·2 /Lg/L exceeds the value quoted by the manufacturers who claim any detectable ( multi-centre study by the same group quotes a cutoff of O·2 JLg/L.5 A second group derived an upper reference limit of O·5 JLg/L. 4 It is our view that a cutoff value of O·2 JLg/L is appropriate and a value of 0·5 JLg/L is too high. Debate continues on the relative merits and demerits of individual test for the detection of myocardial ischaemic damage. We and others have previously shown that CK time series offer one reliable strategy;"? although single CK-MB estimations, when accurately timed and related to time of onset of chest pain, are at least as efficient.t-'? In the studies reported here, direct comparison of identical patients shows that troponin T offers no advantage over CK-MB, or even CK in the unthrombolysed case when sample timing is accurate and patients with symptoms of more than 12 h duration on admission are excluded. This represents the ideal situation which may not be achieved in routine clinical practice. Troponin determination is minimally affected by the vagaries of sample timing, reflecting the reported long period of elevation (12 h to 10 days)' or by thrombolysis. The diagnostic performance of CK-MB is known to reach a peak at 19-24 h from onset of chest pain and to decline thereafter. 10, 11 Troponin T retains diagnostic accuracy up to 48 h from onset of chest pain or 24 h from admission. Hence a single estimation of troponin T 12 h after admission fulfils the criterion of a single diagnostic test to confirm or exclude myocardial infarction.
Analytical considerations and requirements for clinical management must also be considered. We have shown that rapid and inexpensive serial CK determinations allow early ruling out of myocardial infarction.t-" CK-MB can be determined reliably in the emergency laboratory. 12 The comment has been made that early confirmation or exclusion of infarction does not identify the problem patients," those with unstable angina. Troponin T estimations show great potential recognition of those patients with angina at high risk of subsequent cardiac events. Elevated troponin T concentrations were reported in 16 patients originally classified as unstable angina then reclassified as minimal myocardial damage on the basis of retrospective review of CK-MB measurements.! There were four in-hospital deaths in this group, but no long-term follow up data was presented. This group may comprise small myocardial infarcts missed by conventional markers, which is also a possibility in one of our cases presented in Table 2 . We have suggested" that detectable but not diagnostic levels of troponin T are of prognostic significance and a recent publication has suggested that this is the case." Further studies are required to confirm this.
We conclude that a single measurement of troponin T 12-24 h from admission or 12-48 h from onset of chest pain will confirm or exclude myocardial infarction. Use of troponin T to influence patient management prospectively must await the development of assays capable of use in the emergency laboratory. Troponin T may allow reliable prospective diagnosis of unstable angina, but this requires further investigation.
